AMAG Board Says Shareholders Should Vote for Allos Purchase

AMAG Pharmaceuticals Inc. (AMAG), the maker of the anemia drug Feraheme, urged investors today to support its $189 million bid for cancer drugmaker Allos Therapeutics Inc. (ALTH) over the objections of MSMB Capital Management.

MSMB Capital, a New York-based hedge fund that owns 5.9 percent of AMAG, said in a statement yesterday that it opposes AMAG’s attempt to purchase Allos. MSMB in August made an unsolicited $378 million offer for AMAG, based in Lexington, Massachusetts.

AMAG is working with Allos, based in Westminster, Colorado, to complete the all-stock acquisition valued at $2.44 a share when the deal was announced in July. It’s now worth about $1.79 after declines in AMAG’s share price. AMAG investors are scheduled to vote on the Allos acquisition on Oct. 21.

“Do not rely on MSMB Capital’s illusory proposal,” AMAG said in a filing today to investors. “Your Board believes that the combination with Allos will create a financially strong company.”

Allos shares were unchanged at $1.45 at 4 p.m. New York time. AMAG gained 5.3 percent to $13.94.

“Allos shareholders are getting an excellent price -- and AMAG shareholders may be overpaying,” MSMB said in its statement. Martin Shkreli, MSMB’s chief investment officer, said in announcing his takeover bid on Aug. 3 that AMAG had been mismanaged.

AMAG wants to add Allos to acquire its lymphoma drug Folotyn, which AMAG said has a common customer base. AMAG is seeking new revenue after Feraheme failed to meet second-quarter estimates by five analysts surveyed by Bloomberg. Sales of Folotyn may slow though, Citibank analyst Yaron Werber in New York said in an Oct. 5 note to clients that disparaged the deal.

To contact the reporter on this story: Drew Armstrong in Washington at darmstrong17@bloomberg.net;

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.